(229) A Cryogel-Based Dendritic Cell Vaccine Enhances Breast Cancer Post-Surgical Immunotherapy

Introduction: TNBC is one of the most aggressive malignancies worldwide. Surgery is the prior intervention for TNBC patients. However, the residual cancer recurrence often contributes to a worse cancer progression and tumor metastasis. Dendritic cell (DC) vaccine plays a critical role for boosting anti-tumor immune response through evoking the adaptive immune system. However, the therapeutic efficiency is often hindered by the immunosuppressive tumor microenvironment that leading to the failure of DC maturation. Therefore, there is an urgent need for engineering DC vaccine against tumor recurrence.